20 articles
A large WHO pharmacovigilance analysis reveals which myeloma drugs most strongly signal autonomic, motor, and sensory nerve damage.
Novel BRAF inhibitor mosperafenib demonstrates safety and efficacy in patients with advanced cancers, including those resistant to prior treatments.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
Widely-used anesthetic triggers immune system to attack tumors and enhances checkpoint inhibitor therapy effectiveness.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Nationwide French study reveals benzodiazepine use significantly worsens survival outcomes in lung cancer patients receiving pembrolizumab immunotherapy.
Two common antidepressants cause cholesterol buildup in cancer cell lysosomes, triggering immunogenic cell death that helps immune system fight tumors.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Scientists develop brain-penetrating drug that makes glioblastoma cells vulnerable to targeted elimination therapy.
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
A completed Phase II trial tests whether combining two checkpoint inhibitors can safely and effectively treat melanoma that has spread to the brain.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
New research reveals how hepatoma cells evade immunotherapy by secreting N1-acetylspermidine to suppress immune function.
